# AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Source: https://onco.cc/trials/nct05850234/  
OnCo record `nct05850234` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AZD0120 in multiple myeloma, run by AstraZeneca, now recruiting.

## Summary

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1) is a phase 1/2 interventional study registered as NCT05850234 by AstraZeneca, with 232 participants planned, started 2023-07-20 and due to reach its primary completion in 2027-10-01. Interventions recorded: AZD0120.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05850234
- Phase: 1/2
- Setting: A Phase Ib/II Study of AZD0120, Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against CD19 and B-cell Maturation Antigen (BCMA) in Participants With Relapsed/Refractory Multiple Myeloma (DURGA-1)
- Sponsor: AstraZeneca
- Enrolled: 232

## Sources

- ClinicalTrials.gov NCT05850234: https://clinicaltrials.gov/study/NCT05850234

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [AZD0120](https://onco.cc/drugs/azd0120/)
- companies: [AstraZeneca](https://onco.cc/companies/astrazeneca/)

---
JSON: https://onco.cc/api/v1/entities/nct05850234.json